Biofrontera receives Nasdaq notice for minimum bid price non-compliance
Biofrontera Inc., trading under the Nasdaq symbol BFRI, received a notice from the Listing Qualifications Department of The Nasdaq Stock Market on Monday. The company failed to meet Nasdaq Listing Rule 5550(a)(2) as its closing bid price of common stock dropped below $1.00 per share for 30 straight business days. This does not yet result in delisting but gives Biofrontera 180 days, or until May 17, 2027, to restore compliance.
The bid price must stay at or above $1.00 for 10 consecutive trading days during this window. If compliance is not achieved by May 17, 2027, additional compliance periods may be granted if the company meets other listing conditions, such as market value of publicly held shares and provides written intent to cure through a reverse stock split.
Failure to meet these requirements could lead to a delisting notice, allowing the company to appeal to a Nasdaq Hearings Panel. Biofrontera plans to monitor the closing bid price and explore options to resolve the issue and regain compliance.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.